BOUL: Organic growth and strong instrument sales drive improved cash flow amid margin pressure

About this update from Boule Diagnostics Ab

Q3 2025 saw a return to organic growth, strong instrument sales, and improved operating cash flow, despite lower gross margin and negative currency effects. Strategic cost reductions and new product agreements support a higher margin outlook. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Boule Diagnostics Ab